Overview and countermeasures of cancer burden in China

doi:10.1007/s11427-022-2240-6

Review

. 2023 Nov;66(11):2515-2526.

doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.

Overview and countermeasures of cancer burden in China

Yian Wang^{1

2

3}, Qijia Yan⁴, Chunmei Fan², Yongzhen Mo², Yumin Wang⁴, Xiayu Li³, Qianjin Liao¹, Can Guo², Guiyuan Li^{1

2

3}, Zhaoyang Zeng^{1

2}, Wei Xiong^{5

6

7}, He Huang^{8

9

10}

Affiliations

¹ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China.
² Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China.
³ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China.
⁴ Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410078, China.
⁵ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁶ Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁷ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁸ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.
⁹ Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.
¹⁰ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.

PMID: 37071289
PMCID: PMC10111086
DOI: 10.1007/s11427-022-2240-6

Review

Overview and countermeasures of cancer burden in China

Yian Wang et al. Sci China Life Sci. 2023 Nov.

. 2023 Nov;66(11):2515-2526.

doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.

Authors

Affiliations

¹ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China.
² Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China.
³ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China.
⁴ Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410078, China.
⁵ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁶ Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁷ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China. xiongwei@csu.edu.cn.
⁸ NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.
⁹ Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.
¹⁰ Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, 410078, China. huanghe@csu.edu.cn.

PMID: 37071289
PMCID: PMC10111086
DOI: 10.1007/s11427-022-2240-6

Abstract

Cancer is one of the leading causes of human death worldwide. Treatment of cancer exhausts significant medical resources, and the morbidity and mortality caused by cancer is a huge social burden. Cancer has therefore become a serious economic and social problem shared globally. As an increasingly prevalent disease in China, cancer is a huge challenge for the country's healthcare system. Based on recent data published in the Journal of the National Cancer Center on cancer incidence and mortality in China in 2016, we analyzed the current trends in cancer incidence and changes in cancer mortality and survival rate in China. And also, we examined several key risk factors for cancer pathogenesis and discussed potential countermeasures for cancer prevention and treatment in China.

Keywords: China; cancer; countermeasures; incidence; mortality; statistics; survival.

PubMed Disclaimer

Cited by

Relationship between sex differences in drinking, smoking, and exercising and the incidence of malignancies and medical procedures: a cross-sectional study of 21,916 participants in China.
Hao M, Li Y, Ma W, Wang L, Zheng J, Wu Y. Hao M, et al. J Cancer. 2024 Jun 17;15(14):4551-4565. doi: 10.7150/jca.95456. eCollection 2024. J Cancer. 2024. PMID: 39006079 Free PMC article.
HMGA1 is a Prognostic Biomarker and Correlated with Glycolysis in Lung Adenocarcinoma.
Ma Y, Ma X, Du B, Li X, Li Y. Ma Y, et al. J Cancer. 2024 Mar 25;15(10):2913-2927. doi: 10.7150/jca.89056. eCollection 2024. J Cancer. 2024. PMID: 38706894 Free PMC article.
Exploring the association between sleep duration and cancer risk in middle-aged and older Chinese adults: observations from a representative cohort study (2011-2020).
Jiang Y, Gu X, Yang X, Sun A, Sun H. Jiang Y, et al. BMC Public Health. 2024 Jul 8;24(1):1819. doi: 10.1186/s12889-024-19313-z. BMC Public Health. 2024. PMID: 38978056 Free PMC article.
Transcriptome profiling revealed multiple circadian rhythm-related genes associated with common gynecological cancers.
Peng L, Jiang M, Li K, Yu S, Zhao C, Zhang L, Li L. Peng L, et al. Front Oncol. 2025 Jan 29;15:1422122. doi: 10.3389/fonc.2025.1422122. eCollection 2025. Front Oncol. 2025. PMID: 39944833 Free PMC article.
Health utility scores of six common cancers in China measured by SF-6Dv2.
Tao Y, Cao Y, Xu L, Shi J, Leng L, Yang H, Zhai T, Huang W. Tao Y, et al. Health Qual Life Outcomes. 2025 Jan 12;23(1):5. doi: 10.1186/s12955-025-02332-8. Health Qual Life Outcomes. 2025. PMID: 39799326 Free PMC article.

See all "Cited by" articles

References

1. Alipour M. Molecular mechanism of helicobacter pylori-induced gastric cancer. J Gastrointest Canc. 2021;52:23–30. doi: 10.1007/s12029-020-00518-5. - DOI - PMC - PubMed
1. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135. doi: 10.1016/j.metabol.2018.11.001. - DOI - PubMed
1. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16:223–249. doi: 10.1146/annurev-pathol-042020-042741. - DOI - PubMed
1. Bradley SH, Hatton NLF, Aslam R, Bhartia B, Callister ME, Kennedy MP, Mounce LT, Shinkins B, Hamilton WT, Neal RD. Estimating lung cancer risk from chest X-ray and symptoms: a prospective cohort study. Br J Gen Pract. 2021;71:e280–e286. doi: 10.3399/bjgp20X713993. - DOI - PMC - PubMed
1. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–590. doi: 10.1016/S0140-6736(20)30068-4. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Alipour M. Molecular mechanism of helicobacter pylori-induced gastric cancer. J Gastrointest Canc. 2021;52:23–30. doi: 10.1007/s12029-020-00518-5. - DOI - PMC - PubMed

[2] Alipour M. Molecular mechanism of helicobacter pylori-induced gastric cancer. J Gastrointest Canc. 2021;52:23–30. doi: 10.1007/s12029-020-00518-5. - DOI - PMC - PubMed

[3] Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135. doi: 10.1016/j.metabol.2018.11.001. - DOI - PubMed

[4] Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135. doi: 10.1016/j.metabol.2018.11.001. - DOI - PubMed

[5] Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16:223–249. doi: 10.1146/annurev-pathol-042020-042741. - DOI - PubMed

[6] Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16:223–249. doi: 10.1146/annurev-pathol-042020-042741. - DOI - PubMed

[7] Bradley SH, Hatton NLF, Aslam R, Bhartia B, Callister ME, Kennedy MP, Mounce LT, Shinkins B, Hamilton WT, Neal RD. Estimating lung cancer risk from chest X-ray and symptoms: a prospective cohort study. Br J Gen Pract. 2021;71:e280–e286. doi: 10.3399/bjgp20X713993. - DOI - PMC - PubMed

[8] Bradley SH, Hatton NLF, Aslam R, Bhartia B, Callister ME, Kennedy MP, Mounce LT, Shinkins B, Hamilton WT, Neal RD. Estimating lung cancer risk from chest X-ray and symptoms: a prospective cohort study. Br J Gen Pract. 2021;71:e280–e286. doi: 10.3399/bjgp20X713993. - DOI - PMC - PubMed

[9] Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–590. doi: 10.1016/S0140-6736(20)30068-4. - DOI - PMC - PubMed

[10] Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–590. doi: 10.1016/S0140-6736(20)30068-4. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Overview and countermeasures of cancer burden in China

Affiliations

Overview and countermeasures of cancer burden in China

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials